LU503317B1

LU503317B1 - The use of adiponectin-modified islet cells in improving or enhancing islet transplantation outcomes

Info

Publication number: LU503317B1
Application number: LU503317A
Authority: LU
Inventors: Xiaofeng Zheng
Original assignee: West China Hospital Sichuan Univ
Priority date: 2023-01-06
Filing date: 2023-01-06
Publication date: 2023-07-06

Abstract

The present invention relates to the field of biopharmaceuticals and in particular to the modification of Adiponectin to give islet cells antioxidant and/or anti-inflammatory properties, and to the use of islet cell Adiponectin modification in improving or enhancing the effect of homologous islet. The present invention improves the outcome of homozygous islet transplantation by modifying islet cells with lipocalin prior to islet transplantation so that they overexpress lipocalin and have antioxidant and anti-inflammatory properties. During gene therapy, the islet cells are broken down into individual cells, greatly improving the efficiency of viral infection. After gene therapy, the single cells are raised back into functional cell clusters, allowing for great preservation of islet function.

Description

DESCRIPTION

LU503317

THE USE OF ADIPONECTIN-MODIFIED ISLET CELLS IN IMPROVING OR

ENHANCING ISLET TRANSPLANTATION OUTCOMES

FIELD OF THE INVENTION

The present invention relates to the field of biopharmaceuticals and in particular to the use of

Adiponectin modification in islet cells for antioxidant and/or anti-inflammatory applications, and to the use of islet cell Adiponectin modification in improving or enhancing islet transplantation outcomes.

BACKGROUND OF THE RELATED ART

Islet transplantation is considered to be a promising treatment for type 1 diabetes mellitus (TIDM). However, severe islet loss in number and function in the short term after the transplantation procedure limits its widespread use. Even in the absence of immune rejection, as in the case of allogeneic (autologous) islet transplantation, up to 60% of the implanted islets are rapidly destroyed, emphasising the critical role of non-immune factors in regulating the outcome of islet transplantation. In the early post-transplant period, reactive oxygen radicals and inflammatory responses caused by islet isolation and purification and ischaemia-reperfusion are thought to be the main causes of islet loss in the early stages of transplantation. It is therefore important to genetically modify the islets to have antioxidant and anti-inflammatory properties prior to islet transplantation

SUMMARY OF THE INVENTION

In view of this, the present invention provides for the use of Adiponectinmodification in islet cells for antioxidant and/or anti-inflammatory applications, and for the use of islet cell

Adiponectin modification in improving or enhancing the outcome of islet transplantation. The present invention uses an adenovirus-mediated gene therapy system to modify islet cells prior to islet transplantation to overexpress lipocalin and to have antioxidant and anti-inflammatory properties.

To achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

This invention provides information on the use of Adiponectin, a biologically active peptide produced and secreted by adipocytes, in improving or enhancing the effects of islet 509917 transplantation. Adiponectin is a bioactive peptide produced and secreted by adipocytes.

The present invention also provides the application of Adiponectin modification in antioxidant and/or anti-inflammatory in pancreatic islet cells.

More importantly, the invention also provides for the use of islet cell Adiponectin modification in improving or enhancing the outcome of islet transplants of the same species.

In some specific embodiments of the present invention, the Adiponectin modified islet cells are insulin cells overexpressing Adiponectin.

In some specific embodiments of the present invention, based on adenovirus-mediated.

The present invention also provides methods for making islet cells have antioxidant and/or anti- inflammatory properties to improve or enhance the effect of homogeneous islet islet transplantation effect, comprising the steps of:

Step 1: Preparation of dispersed pancreatic islet cells;

Step 2: Adenovirus-mediated islet cell modification by Adiponectin to obtain lipocalin-modified islet cells;

Step 3: Adiponectin-modified islet cells are taken, washed and cultured to obtain islet mass.

In some specific embodiments of the present invention, the islet cells dispersed in step 1 are prepared using a 0 .25% Trypsin-EDTA solution treated with .

In some specific embodiments of the present invention, the islet cells described in step 2 are treated with Ad-APN-GFP.

In some specific embodiments of the present invention, the cleaning described in step 3 is 2 washes with HBSS solution.

In some specific embodiments of the present invention, the culture described in step 3 is to inoculate described Adiponectin-modified islet cells at a cell concentration of 1 x 105/ml in a non-adhesive culture medium for 4 days in RPMI-1640 medium until islet-like clusters are formed.

The invention improves the outcome of islet transplantation with homologous islets by modifying islet cells with lipocalin prior to islet transplantation so that they overexpress lipocalin and have antioxidant and anti-inflammatory properties. During the gene therapy process, islet cells are broken down into individual cells, greatly improving the efficiency of viral infection.

After gene therapy, the single cells are reared into a functional cell mass and islet function is greatly preserved.

BRIEF DESCRIPTION OF THE DRAWINGS LU503317

To illustrate more clearly the technical solutions in the embodiments or prior art of the invention, the following is a brief description of the accompanying drawings that need to be used in the description of the embodiments or prior art.

Figure 1 shows information about the PAd-APN-GFP plasmid.

Figure 2 shows adenovirus-mediated APN gene transfer in pancreatic islet cells; where, A. fluorescence imaging analysis of pancreatic islet cells 72 hr after adenovirus (Ad-GFP) transfection, scale bar = 50 um. A. Fluorescence imaging analysis of pancreatic islet cells at 72 hr post-transfection with Ad-GFP, scale bar = 50 um; B. Islet cells were transfected with Ad-

APN-GFP (Ad-APN) and islet cells were transfected with Ad-APN-GFP (Ad-APN) and its control Ad-GFP at the indicated times. qPCR analysis of mRNA expression levels of APN in pancreatic islet cells (n = 5); C. Islet cells were transfected with Ad-APN-GFP (Ad-APN) and its control Ad-GFP for the indicated times, and WB analysis of the protein expression levels of

APN in islet cells (n = 5). D. Glucose-stimulated indices to calculate the level of insulin secretion in pancreatic islet cells under 20 mmol/L and 2.8 mmol/L glucose stimulation (n = 5). glucose stimulation (n = 5); E. Islet cells were transfected with Ad-APN-GFP (Ad-APN) for 72 h after Flow analysis of islet cell apoptosis (PI-positive cells)

Figure 3 shows the formation of islet-like clusters from islet monocytes; where A. Islet-like clusters were stained with PI solution and subjected to fluorescence imaging, scale bar = 50 um.

A. Islet-like clusters were stained with PI solution and imaged fluorescently, scale bar = 50 um,

PI-positive cells were dead cells and live cells transfected with Ad-APN-GFP expressed GFP; B.

The proportion of PI proportion of positive cells counted (n = 4)

Figure 4 shows damage caused by oxidative stress and inflammatory responses to peroxide that

APN can make islets resistant to; where A. MDA levels in islets as an indicator of oxidative stress; B. TNF-a levels released from islets; C and D. Expression of the inflammatory factor

COX2 in islets as measured by WB and quantified. Figure 5 shows islet transplantation in subperitoneal homozygous mice; in which, A. Blood glucose levels in islet-transplanted animals were monitored until 30 days after islet removal (n = 6); B. Area under the glucose curve from 2 to 28 days after islet transplantation; C and D. Mouse glucose tolerance assay and area under the glucose curve (n = 3); E. Insulin (red) and CD31 (green) were measured at the site of islet implantation 30 days after islet transplantation. CD31 (green) were stained fluorescently at the islet implantation site; F-G. Quantification of the area of insulin and CD31-positive areas in E plots.

In the picture: 1. Piston, ring groove 11, piston pin seat 12, combustion chamber 2, spherical crown boss 21, vortex groove area 22, thermal barrier coating 3, bonding coating 31 and ceramic 509917 coating 32.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention discloses the use of Adiponectin-modified islet cells in improving or enhancing the effect of islet transplantation, preparation of antioxidant and/or anti-inflammatory drugs, which can be achieved by those skilled in the art by drawing on the contents herein and improving the process parameters as appropriate. In particular, it should be noted that all similar substitutions and modifications that would be obvious to those skilled in the art are considered to be included in the present invention. The methods and applications of the present invention have been described by way of preferred embodiments and it is obvious that those concerned can implement and apply the techniques of the present invention by making changes or appropriate variations and combinations to the methods and applications described herein without departing from the content, spirit and scope of the present invention.

The Adiponectin-modified islet cells provided by the present invention are used in improving or enhancing the effect of islet transplantation, in the preparation of antioxidant and/or anti-inflammatory drugs, the raw materials and reagents used are commercially available.

The invention is further elaborated below in connection with the embodiments:

Example 1 Preparation of adenovirus

The adenovirus-mediated lipocalin overexpression system and its controls (Ad-APN-GFP and Ad-GFP) were commissioned from Shanghai Gikai Genes were prepared. The plasmid information is shown in Figure 1. High concentrations of purified Ad-APN-GFP were obtained.

Example 2 Adenovirus-mediated APN gene transfer in pancreatic islet cells

In the traditional method, the islet mass was treated with adenovirus, but the adenovirus could only infect the outermost 1-2 layers of the islet mass. The cells in the middle of the islets were difficult to be infected and the transfection efficiency was low. In order to improve the transfection efficiency of islets by adenovirus We first treated the islets with 0.25% Trypsin-

EDTA solution to disperse them into single cells. Then, we treated the dispersed islet cells (60,000 cells/ml medium) with Ad-APN-GFP (6000 virus particles/ul medium) treated with a multiplicity of infection (MOI) of 100 (100 virus particles/one cell). At 72 h post-transfection, almost all islet cells cells expressed GFP (Figure 2A), with transfection efficiency close to 100%.

At 24, 36, 48 and 72 hours post-transfection, we further determined the expression of GFP by

RT-PCR and WB. by RT-PCR and WB to detect the expression of APN in pancreatic islet cells. mRNA and protein expression of APN in pancreatic islet cells were significantly increased at 36 h post-transfection (Figure 2B-C). While adenovirus-mediated APN gene transfer in pancreatic islet cells had a significant effect on islet cell function and survival were not significantly "| ’ affected (Figure 2D-E).

Example 3 Polymerisation of dispersed islet cells into functional islet-like clusters

To restore the islet cells to a function similar to that of the primary islet mass, the dispersed islet monocytes were washed twice with HBSS solution after viral After transfection, they were washed twice with HBSS solution and then inoculated at a concentration of 2 x 105 cells/dish in mm ultra-low-adhesion dishes. The cells were cultured in RPMI-1640 medium for 4 days until islet-like clusters were formed (Figure 3A). The cellular activity of islet-like cells was higher than 95% (Figure 3B).

Example 4 Sub-peritoneal islet transplantation in homozygous mice

Prior to islet transplantation, recipient Balb/c mice (8-10 weeks, males) were injected intraperitoneally with streptozotocin (200 mg/kg, Sigma-Aldrich) to induce type 1 diabetes and monitored daily for health status; no animals showed signs of severe disease or died. We then randomly divided the recipient diabetic mice into 2 groups by:

Renal peritoneal islet transplantation: 1). The mice were anesthetized with 1% isoflurane and their abdomens were debrided and their kidneys surgically exposed. 2). A 0.2 cm long incision is made on the surface of the kidney with a 27-gauge needle and a glass capillary tube is inserted through the incision inserted to create a slit between the kidney and the peritoneum. 3). The isolated islets are aspirated using a tube with a microsyringe attached and inverted so that the islets collect in the tube out of the mouth. 4). Insert the tube with the islet through the reserved gap and slowly inject the islet and carefully pull out the tube. 150 islet equivalents were transplanted into the islets under the peritoneal membrane (after islet transplantation, reactive oxygen species or inflammation can cause islet death or loss of function, and large amounts of islets (1000 equivalents) are usually required to cure diabetes. 150 islet equivalents are not sufficient to cure diabetes, as shown in Figure 4A, and can maintain blood glucose in the normal range in diabetic rats for 2 weeks after transplantation, but then blood glucose rises again. In contrast, the same 150 islet equivalents of Ad-APN-treated islets can keep the blood glucose of diabetic rats in the normal range.) Ad-APN or Ad-GFP-transfected islet-like clusters. After transplantation, animals were tested for random blood glucose every two days and a glucose tolerance test was performed on day 30 post-transplantation, the same day the kidneys were surgically removed. Our results showed that Ad-GFP-transfected islets only suppressed hyperglycaemia in diabetic animals in the early post-transplant period and failed to maintain their normal blood glucose two weeks after transplantation, whereas Ad-APN-GEP 0 (Ad-APN)-transfected islets effectively controlled the animals’ blood glucose in the normal range for 30 days prior to nephrectomy (Figure 4A-B). Interestingly, the Ad-adiponectin-GFP- transfected group became hyperglycaemic again after nephrectomy on day 30 post- transplantation, suggesting that the islet mass transplanted into the renal envelope played a key role in maintaining blood glucose in the recipient diabetic rats (Figure SA). Furthermore, at day post-transplantation, glucose tolerance was significantly higher in the Ad-APN-GFP- transfected group compared to the Ad-GFP-transfected group (Figure 5C-D). By fluorescence immunostaining of excised kidneys with islet masses, we found that insulin and CD31 positive areas were significantly higher in the Ad-APN-transfected group than in the Ad-GFP-transfected group, indicating that the islet masses in the Ad-APN-transfected group were better protected with better vascularisation (Figure 5C-D). The islets in the surface Ad-APN-transfected group were better protected and had better vascularization (Figure SE-G).

The foregoing is only a preferred embodiment of the invention and it should be noted that for those of ordinary skill in the art there are a number of improvements and modifications that can be made without departing from the principles of the invention. It should be noted that for a person of ordinary skill in the art, a number of improvements and embellishments can be made without departing from the principles of the present invention, and these improvements and embellishments should also These improvements and embellishments shall also be considered within the scope of protection of the present invention.

Claims

CLAIMS LU503317

1. The use of Adiponectin in the preparation of drugs to improve or enhance the effect of islet transplantation.

2. The use of Adiponectin modification in the preparation of antioxidant and/or anti- inflammatory agents for pancreatic islet cells.

3. Application of Adiponectin-modified islet cells in the preparation of a drug for improving or enhancing the effect of islet transplantation of the same.

4.The application as in claim 3, characterized in that the Adiponectin-modified islet cells are insulin cells overexpressing Adiponectin.

5. The application as claimed in any one of claims 1 to 4, characterised in that it is based on adenovirus-mediated.

6. Method for improving or enhancing the effect of islet transplantation, characterised in that it comprises the steps: step 1: preparing dispersed islet cells. step 2:obtaining Adiponectin-modified islet cells by adenovirus-mediated modification of the islet cells by taking the islet cells by Adiponectin. step 3: taking the Adiponectin-modified islet cells, washing them, culturing them and obtaining islet masses.

7 . The method as in claim 6, characterized in that the islet cells dispersed in step 1 are prepared by treatment with a 0 .25% Trypsin-EDTA solution.

8. The method as claimed in claim 6 or 7, characterized in that the islet cells in step 2 are treated with Ad-APN-GFP.

9. The method as claimed in any one of claims 6 to 8, characterized in that the washing in step 3 is done twice using HBSS solution.

10 . The method as claimed in any one of claims 6 to 9, characterized in that the culture in step 3 consists of inoculating said Adiponectin-modified islet cells in a non-adhesive culture medium at a cell concentration of 1 x 105/ml and culturing in RPMI-1640 medium for 4 days until islet-like clusters are formed.